Age-Related Macular Degeneration Bibliography

  Downloads  Fellow Members Only

AMD Review/Classification

Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.

Ferris FL 3rd, Wilkinson CP, Bird A, et al. Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration.Ophthalmology. 2013;120(4):844-851.

AMD Epidemiology

Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE.  Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.  Ophthalmology. 2007;114:253–262.

Chakravarthy U, Wong TY, Fletcher A, et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.  BMC Ophthalmol. 2010;10:31.

AMD Genetics

Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151-171. 

Klein RJ, Zeiss C, Chew EY, et al.  Complement factor H polymorphism in age-related macular degeneration.  Science. 2005;308:385–389.

AMD and Depression

Casten RJ, Rovner BW. Update on depression and age-related macular degeneration.  Curr Opin Ophthalmol. 2013;24(3):239-243.

AREDS /AREDS2 Trial

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no 8.  Age-Related Eye Disease Study Research Group.  Arch Ophthalmol. 2001;119:1417–1436.

Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.  Age-Related Eye Disease Study 2 (AREDS2) Research Group. JAMA Ophthalmol. 2014;132(2):142-149.

Aronow ME, Chew EY. Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions.  Curr Opin Ophthalmol. 2014;25(3):186-190.

Macular Photocoagulation Study

Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial.  Macular Photocoagulation Study Group.  Arch Ophthalmol. 1982;100:912–918. 

Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group.  Arch Ophthalmol.1991;109(8):1109-1114.

Photodynamic Therapy/ Visudyne

NM Bressler.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.  Arch Ophthalmol. 2001;119:198–207.

Ranibizumab

Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.

Ranibizumab vs Bevicizumab (CATT Trial) and Safety

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.  Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.  N Engl J Med. 2011;364:1897–1908.

Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.  Cochrane Database Syst Rev. 2014;15;9.

Aflibercept

Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. VIEW 1 and VIEW 2 Study Groups.  Ophthalmology. 2012;119(12):2537-2548.

Stem Cells

Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies.  Lancet. 2014 Oct 15. pii: S0140-6736(14)61376-3.